Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Journal of Hainan Medical University ; 26(20):1527-1530, 2020.
Article in Chinese | GIM | ID: covidwho-2145373

ABSTRACT

COVID-19 belongs to the plague category of Traditional Chinese Medicine. It has been confirmed in many ancient books and modern clinical studies that the acupuncture and moxibustion can cure the plague. Containing COVID-19, National Health Commission of the People's Republic of China and National Administration of Traditional Chinese Medicine Jointly issued the Diagnosis and Treatment of Corona Virus Disease-19(7th edition). It mentions the treatment program of acupuncture and moxibustion participating in the prevention and treatment of COVID-19. Liu Baoyan's team analyzed the ideas of acupuncture and moxibustion treatment for COVID-19. However, the clinical advantages of acupuncture and moxibustion still need to be further clarified. In the treatment of many clinical symptoms of COVID-19, acupuncture therapy has a good clinical effect, so the purpose of our discussion on the advantages is to improve the clinical accuracy and efficacy of COVID-19.

2.
Medicinal Plant ; 13(1):84-94, 2022.
Article in English | CAB Abstracts | ID: covidwho-2026016

ABSTRACT

Post-traumatic stress disorder(PTSD) is a kind of mental disorder caused by severe traumatic events. It has a high incidence, a serious of impacts on the physical and mental health of patients. Especially in the current situation of COVID-19, the researches on PTSD are particularly important, but the choice of drugs available for PTSD is limited and it is often accompanied by adverse reactions. In the field of acupuncture, there are many clinical research evidences suggested that PTSD is a predominant disease of acupuncture. However, its action mechanisms have not been fully elucidated, so the possible mechanisms of acupuncture in treating PTSD were discussed.

3.
Nat Commun ; 12(1): 668, 2021 01 28.
Article in English | MEDLINE | ID: covidwho-1387328

ABSTRACT

Except remdesivir, no specific antivirals for SARS-CoV-2 infection are currently available. Here, we characterize two small-molecule-compounds, named GRL-1720 and 5h, containing an indoline and indole moiety, respectively, which target the SARS-CoV-2 main protease (Mpro). We use VeroE6 cell-based assays with RNA-qPCR, cytopathic assays, and immunocytochemistry and show both compounds to block the infectivity of SARS-CoV-2 with EC50 values of 15 ± 4 and 4.2 ± 0.7 µM for GRL-1720 and 5h, respectively. Remdesivir permitted viral breakthrough at high concentrations; however, compound 5h completely blocks SARS-CoV-2 infection in vitro without viral breakthrough or detectable cytotoxicity. Combination of 5h and remdesivir exhibits synergism against SARS-CoV-2. Additional X-ray structural analysis show that 5h forms a covalent bond with Mpro and makes polar interactions with multiple active site amino acid residues. The present data suggest that 5h might serve as a lead Mpro inhibitor for the development of therapeutics for SARS-CoV-2 infection.


Subject(s)
COVID-19 Drug Treatment , Coronavirus Protease Inhibitors/pharmacology , SARS-CoV-2/drug effects , Viral Proteases/drug effects , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/pharmacology , Alanine/analogs & derivatives , Alanine/pharmacology , Animals , Antiviral Agents/pharmacology , Cell Line , Chlorocebus aethiops , Humans , Indoles/pharmacology , Pyridines/pharmacology , Vero Cells , Viral Proteases/metabolism
5.
Front Cardiovasc Med ; 7: 585220, 2020.
Article in English | MEDLINE | ID: covidwho-1052488

ABSTRACT

Background: Myocardial injury is a life-threatening complication of coronavirus disease 2019 (COVID-19). Pre-existing health conditions and early morphological alterations may precipitate cardiac injury and dysfunction after contracting the virus. The current study aimed at assessing potential risk factors for COVID-19 cardiac complications in patients with pre-existing conditions and imaging predictors. Methods and Results: The multi-center, retrospective cohort study consecutively enrolled 400 patients with lab-confirmed COVID-19 in six Chinese hospitals remote to the Wuhan epicenter. Patients were diagnosed with or without the complication of myocardial injury by history and cardiac biomarker Troponin I/T (TnI/T) elevation above the 99th percentile upper reference limit. The majority of COVID-19 patients with myocardial injury exhibited pre-existing health conditions, such as hypertension, diabetes, hypercholesterolemia, and coronary disease. They had increased levels of the inflammatory cytokine interleukin-6 and more in-hospital adverse events (admission to an intensive care unit, invasive mechanical ventilation, or death). Chest CT scan on admission demonstrated that COVID-19 patients with myocardial injury had higher epicardial adipose tissue volume ([EATV] 139.1 (83.8-195.9) vs. 92.6 (76.2-134.4) cm2; P = 0.036). The optimal EATV cut-off value (137.1 cm2) served as a useful factor for assessing myocardial injury, which yielded sensitivity and specificity of 55.0% (95%CI, 32.0-76.2%) and 77.4% (95%CI, 71.6-82.3%) in adverse cardiac events, respectively. Multivariate logistic regression analysis showed that EATV over 137.1 cm2 was a strong independent predictor for myocardial injury in patients with COVID-19 [OR 3.058, (95%CI, 1.032-9.063); P = 0.044]. Conclusions: Augmented EATV on admission chest CT scan, together with the pre-existing health conditions (hypertension, diabetes, and hyperlipidemia) and inflammatory cytokine production, is associated with increased myocardial injury and mortality in COVID-19 patients. Assessment of pre-existing conditions and chest CT scan EATV on admission may provide a threshold point potentially useful for predicting cardiovascular complications of COVID-19.

6.
Epidemiol Infect ; 149: e4, 2021 01 05.
Article in English | MEDLINE | ID: covidwho-1047897

ABSTRACT

Hypertension represents one of the most common pre-existing conditions and comorbidities in Coronavirus disease 2019 (COVID-19) patients. To explore whether hypertension serves as a risk factor for disease severity, a multi-centre, retrospective study was conducted in COVID-19 patients. A total of 498 consecutively hospitalised patients with lab-confirmed COVID-19 in China were enrolled in this cohort. Using logistic regression, we assessed the association between hypertension and the likelihood of severe illness with adjustment for confounders. We observed that more than 16% of the enrolled patients exhibited pre-existing hypertension on admission. More severe COVID-19 cases occurred in individuals with hypertension than those without hypertension (21% vs. 10%, P = 0.007). Hypertension associated with the increased risk of severe illness, which was not modified by other demographic factors, such as age, sex, hospital geological location and blood pressure levels on admission. More attention and treatment should be offered to patients with underlying hypertension, who usually are older, have more comorbidities and more susceptible to cardiac complications.


Subject(s)
COVID-19/complications , Hypertension/complications , Adult , Aged , COVID-19/diagnosis , China , Comorbidity , Female , Hospitalization , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL